EGFR and non-small cell lung carcinoma: First, the CheckMate-722 trial randomized 294 patients from USA and southeastern Asia with EGFR-mutated NSCLC and progression on first- (or second-)line TKI 1:1 to receive nivolumab and chemotherapy or chemotherapy alone [38].